Simian adenovirus and hybrid adenoviral vectors
AssigneeOxford University Innovation Limited
InventorsMatthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
Life of this patent
Estimating the term…
Abstract
Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.
Claims22
A method of ameliorating, treating or preventing cancer using immunotherapy, said immunotherapy comprising:
- administering a vaccine comprising:
- an adenovirus to a subject in need of such treatment, wherein the adenovirus vector comprising a capsid, wherein said capsid comprises:
- one or more capsid proteins derived from chimpanzee adenovirus AdY25 and encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest operably linked to expression control sequences which direct the expression thereof in an animal cell and an adenoviral packaging signal sequence, and wherein the nucleotide sequence that encodes the wild-type chimpanzee adenovirus AdY25 is SEQ ID NO:1.
(canceled)
(canceled)
A method of treating cancer using immunotherapy, said immunotherapy comprising administering a vaccine comprising an isolated nucleic acid molecule having a sequence at least 90% identical to SEQ ID NO. 1 over its entire length to a subject in need of such treatment.
Dependencies are inferred from the claim text.